Light Responsive Iron Chelator: New Suncreen Ingredient That Heals Sunburn, Prevents Skin Cancer
According to a research published in the Journal of Investigative Dermatology, sunburn sufferers can soon benefit from a new sunscreen ingredient that actively repairs sunburnt skin and helps prevent the onset of skin cancer.
Conventional sunscreen lotions only as UVA and UVB sunlight filter.
This new ingredient releases an active ingredient that sequesters free iron released when the skin burns: thereby reducing the inflammation and pain that goes with sunburn (worsened by iron) and preventing the build up of harmful sunlight-generated free radicals (which can lead to the development of skin cancers).
This new ingredient, an iron chelator, is light-responsive and only becomes active once exposed to UV radiation in sunlight, avoiding any side-effects that might result from long-term exposure to the active form of the drug.
Clinical trials are expected in the next two to three years.
Dr. Charareh Pourzand from the University of Bath is working in collaboration with Dr. James Dowden (presently at Nottingham University) in this study.
The research team was able to design two commercially attractive prototypes (currently in laboratory trials) after three years of research. These prototypes contain ‘caged’ iron binding sites which release the chelators only in response to high doses of UV light, thus avoiding toxicity to cells.
The original research paper entitled: “Caged-Iron Chelators a Novel Approach Towards Protecting Skin Cells Against UV A-Induced Necrotic Cell Death”, is available online from the Journal for Investigative Dermatology.
Read more at University of Bath.
Tags: iron-chelator, skin-cancer, sunburn, sunlight-filter, sunscreen-lotionRelated Stories
POSTED IN: on anti-cancer ingredients, on skin cancer
0 opinions for Light Responsive Iron Chelator: New Suncreen Ingredient That Heals Sunburn, Prevents Skin Cancer
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: